Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71906 | 0.90 | MEN1 (0.45) | MEN1KMT2AGLP1RRECQLTSHR | |
| SCHEMBL71138 | 0.89 | EPHX2 (0.41) | GLP1RCASP2TSHR | |
| SCHEMBL13805652 | 0.85 | GLP1R (0.49) | MEN1KMT2AGLP1RCASP2RECQL | |
| SCHEMBL16593142 | 0.84 | MEN1 (0.63) | MEN1KMT2ACASP2RECQLNAAA | |
| SCHEMBL13805654 | 0.84 | GLP1R (0.53) | MEN1KMT2AGLP1RCASP2RECQL | |
| SCHEMBL13805653 | 0.83 | GLP1R (0.57) | GLP1RCASP2NAAA | |
| SCHEMBL71147 | 0.82 | GLP1R (0.46) | MEN1KMT2AGLP1RCASP2RECQL | |
| SCHEMBL14683467 | 0.82 | GLP1R (0.44) | MEN1KMT2AGLP1RRECQLTSHR | |
| SCHEMBL14683527 | 0.82 | GLP1R (0.44) | MEN1KMT2AGLP1RTSHRALDH1A1 | |
| SCHEMBL71315 | 0.82 | GLP1R (0.46) | MEN1KMT2AGLP1RCASP2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | MEN1 922/4885KMT2A 2972/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.